Hearing loss, autosomal recessive
MONDO:0019588Autosomal recessive form of nonsyndromic deafness.
Also known as: hearing loss, autosomal recessive, autosomal recessive isolated neurosensory deafness type DFNB, autosomal recessive isolated sensorineural deafness type DFNB, autosomal recessive non-syndromic neurosensory deafness type DFNB, autosomal recessive non-syndromic sensorineural deafness type DFNB, autosomal recessive nonsyndromic deafness, autosomal recessive nonsyndromic genetic deafness, deafness, autosomal recessive
17 clinical trials for this condition and its sub-types, 1 tagged with Hearing loss, autosomal recessive itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hearing loss, autosomal recessive
-
Hearing loss, autosomal recessive 57 0 trials
-
Hearing loss, autosomal recessive 94 0 trials
-
Hearing loss, autosomal recessive 99 0 trials
-
Can a gene therapy restore natural hearing after cochlear implants?
Cure OngoingThis trial tests an experimental gene therapy called EA0010 in children aged 1 to 17 with hearing loss caused by mutations in the OTOF gene, who already have cochlear implants. The therapy is injected into one ear and aims to deliver a working copy of the OTOF gene to inner ear c…
Sponsor: Shanghai EmayGene Technology Co., Ltd • Aim: Cure
Last updated Aug 14, 2026 00:00 UTC
-
One-Time injection aims to restore hearing in children born deaf
Cure OngoingThis trial tests a gene therapy called SENS-501 for children aged 6 to 31 months who are severely or profoundly deaf due to mutations in the otoferlin gene. The therapy is injected directly into one inner ear to deliver a working copy of the gene. The goal is to restore natural h…
Phase 1/2 • Sponsor: Sensorion • Aim: Cure
Last updated Jul 10, 2026 00:00 UTC
-
New hope for hard-to-treat lung cancer: experimental drug targets MET gene
Disease control OngoingThis study tests an experimental drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The first part finds a safe dose, and the second part checks if the drug can shrink tumors. About 231 participants will take part.
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Gene therapy for deafness: researchers track long-term safety and hearing gains
Disease control By invitation onlyThis study follows 30 people who previously received a gene therapy (AAVAnc80-hOTOF) for hearing loss caused by otoferlin gene mutations. Researchers will monitor safety over the long term, checking for late side effects, and measure hearing improvements using brain response test…
Sponsor: Akouos, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New injection hopes to heal scarred vocal cords and restore voice
Symptom relief OngoingThis study tests an injection called KP-100LI for people with vocal fold scars that cause voice problems. About 62 adults will receive either the study drug or a placebo to see if it improves voice function over 24 weeks. The goal is to confirm the treatment is safe and effective…
Phase 3 • Sponsor: Kringle Pharma, Inc. • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Scientists map rare blindness to speed future cures
Knowledge-focused OngoingThis study follows 44 people with a rare genetic form of Usher syndrome caused by PCDH15 mutations. Over 48 months, researchers measure how their vision changes using eye exams and imaging. The goal is to identify the best ways to track disease progression, which will help design…
Sponsor: Jaeb Center for Health Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC